Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Three-Year Data of PRADO and OpACIN-Neo Trials - The Impact of Response-Directed Surgery & Adjuvant Therapy on Long-Term Survival After Neoadjuvant Ipi + Nivo in Stage III Melanoma"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Irene Reijers
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Irene Reijers
Comments 0
Login to view comments.
Click here to Login
